PMID- 20038404
OWN - NLM
STAT- MEDLINE
DCOM- 20100422
LR  - 20190917
IS  - 1579-2242 (Electronic)
IS  - 0300-8932 (Linking)
VI  - 62
IP  - 12
DP  - 2009 Dec
TI  - Sex hormone-binding globulin: a new marker of disease severity and prognosis in 
      men with chronic heart failure.
PG  - 1381-7
AB  - INTRODUCTION AND OBJECTIVES: Sex hormone-binding globulin (SHBG) is a key 
      regulator of the actions of anabolic steroids. Chronic heart failure (HF) has 
      been associated with anabolic steroid deficiency, but its relationship with SHBG 
      is not known. METHODS: The study involved 104 men (53+/-11 years) with HF (i.e. 
      left ventricular ejection fraction [LVEF] <40%) attending a specialist clinic on 
      optimum treatment and in a stable condition. At enrolment, the median and 
      interquartile range (IQR) SHBG level was determined, associated hormone levels 
      were measured, and known risk factors were recorded. The study end-point was 
      cardiac death within 3 years. RESULTS: At enrolment, the SHBG level (median 34.5 
      nmol/L, IQR 27-50 nmol/L) was correlated with the N-terminal probrain natriuretic 
      peptide level (r=0.271, P=.005), LVEF (r=-0.263, P=.007), body mass index 
      (r=-0.199, P=.020) and total testosterone level (r=0.332, P=.001). The median 
      SHBG level was higher in the 16 patients (15.4%) who died, at 48.5 nmol/L (IQR 
      36-69.5 nmol/L) vs. 33 nmol/L (IQR 25.3-48.7 nmol/L; P=.001), and a high level 
      was associated with an increased risk of death (hazard ratio [HR]=1.045, 95% 
      confidence interval [CI] 1.021-1.069; P< .001). The association remained 
      significant after adjustment in Cox multivariate regression modeling, at HR=1.049 
      (95% CI 1.020-1.079; P=.001). Analysis by SHBG tertiles showed mortality was 30% 
      in the third tertile, 14% in the second, and 4% in the first (log rank 0.007; 
      HR=3.25, 95% CI 1.43-7.34; P=.004). CONCLUSIONS: The SHBG level correlated with 
      measures of HF severity and was associated with a higher risk of cardiac death. 
      Further studies are needed to clarify whether SHBG plays a role in HF 
      pathophysiology.
FAU - Pascual-Figal, Domingo A
AU  - Pascual-Figal DA
AD  - Unidad de Insuficiencia Cardiaca, Servicio de Cardiologia, Hospital Universitario 
      Virgen de la Arrixaca, Departamento de Medicina, Facultad de Medicina, 
      Universidad de Murcia, El Palmar, 30120 Murcia, Espana. dapascual@servicam.com
FAU - Tornel, Pedro L
AU  - Tornel PL
FAU - Nicolas, Francisco
AU  - Nicolas F
FAU - Sanchez-Mas, Jesus
AU  - Sanchez-Mas J
FAU - Martinez, Maria D
AU  - Martinez MD
FAU - Gracia, Maria R
AU  - Gracia MR
FAU - Garrido, Iris P
AU  - Garrido IP
FAU - Ruiperez, Juan A
AU  - Ruiperez JA
FAU - Valdes, Mariano
AU  - Valdes M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Spain
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
RN  - 0 (Biomarkers)
RN  - 0 (Sex Hormone-Binding Globulin)
SB  - IM
MH  - Biomarkers/blood
MH  - Heart Failure/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Severity of Illness Index
MH  - Sex Hormone-Binding Globulin/*analysis
EDAT- 2009/12/30 06:00
MHDA- 2010/04/23 06:00
CRDT- 2009/12/30 06:00
PHST- 2009/12/30 06:00 [entrez]
PHST- 2009/12/30 06:00 [pubmed]
PHST- 2010/04/23 06:00 [medline]
AID - 13145640 [pii]
AID - 10.1016/s1885-5857(09)73532-7 [doi]
PST - ppublish
SO  - Rev Esp Cardiol. 2009 Dec;62(12):1381-7. doi: 10.1016/s1885-5857(09)73532-7.